

## MYDECINE INNOVATIONS GROUP INC.

### MYDECINE ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT OF SECURED CONVERTIBLE DEBENTURES

Vancouver, BC, October 16, 2020 - Mydecine Innovations Group Inc. (CSE:MYCO) (OTC: MYCOF) (FSE:ONF) ("Mydecine" or the "Company") is pleased to announce that today it has successfully closed its previously announced non-brokered private placement (the "**Offering**") of secured convertible debenture notes (the "**Debentures**"). Pursuant to the Offering, the Company placed an aggregate of C\$4.7 million Debentures.

Prior to closing, the Company sought confidential price protection from the Canadian Securities Exchange (the "**CSE**") for the Offering and was granted an exemption to the pricing restrictions on the Debentures. The CSE required a shareholder resolution evidencing majority approval in order to grant the exemption. The Company successfully obtained the required written shareholder approval prior to closing the Offering.

Each Debenture has a maturity date of twelve (12) months from the closing date (the "**Maturity Date**") and bears interest at the rate of 10% per annum. The principal amount and any unpaid accrued interest on each Debenture is payable in cash on the Maturity Date. Each Debenture holder may, in its sole discretion and at any time up to the Maturity Date, convert the principal amount of the subject Debenture, in whole or in part, and all accrued but unpaid interest, into conversion units (each a "**Conversion Unit**", and collectively, the "**Conversion Units**") at a conversion rate of \$0.20 per Conversion Unit. Each Conversion Unit will consist of one (1) common share of the Company (each, a "**Conversion Share**") and one (1) common share purchase warrant (each, a "**Conversion Warrant**") with each Conversion Warrant entitling the holder thereof to purchase one (1) additional common share (each, a "**Warrant Share**") of the Company at a price of \$0.30 per Warrant Share for a period of twenty-four (24) months from the issuance date of the Conversion Warrant. The Debentures are secured by way of a general security agreement made in favour of a collateral agent acting as agent for all of the holders of the Debentures, granting a first priority security interest in all of the Company's assets. The Company has the right to prepay a part of or the entire principal amount of the Debentures at any time without penalty.

The Company intends to use the net proceeds from the Offering for capital projects and for general working capital purposes.

The Debentures, Conversion Shares, Warrants and Warrant Shares (collectively, the "**Securities**") have been issued on a private placement basis pursuant to applicable exemptions from prospectus requirements under applicable securities laws, and as such, will be subject to a statutory hold period of four months and one day from the applicable issuance date.

The Securities have not been nor will they be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and such securities may therefore not be offered or sold in the United States or to or for the account or benefit of a person in the United States or a U.S. Person (as defined in Regulation S of the U.S. Securities Act) absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

*NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.*

## **About Mydecine Innovations Group Inc.**

[Mydecine Innovations Group™](#) is a publicly traded life sciences parent company with offices in Denver, CO and Vancouver, BC. Mydecine™ is dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine's experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development, including synthesis, genetic research, import/export, delivery system design, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

For further information about Mydecine Innovations Group Inc., please consult the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) or visit the Company's website at <http://mydecine.com/>. For further information about We Are Kured, please visit their website at [www.wearekured.com](http://www.wearekured.com).

### **On Behalf of the Board of Directors**

Joshua Bartch  
Chief Executive Officer

### **For Further Information Contact**

Corporate Communications  
250-488-6728

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.